Table 2 Primary and secondary outcome measures follow up data

GDS

12.23(5.22) n = 13

12.00 (4.26) n = 14

0.59 0.11(CI -2.59, 4.38)

11.50 (6.66) n = 14

11.88 (4.88) n = 18

0.08 0.35 (-0.58,8.43)

CES-D

18.27 (7.54) n = 11

15.27 (6.53) n = 15

0.94 0.01(CI -4.55, 4.90)

15.28 (9.90) n = 14

14.44 (7.24) n = 18

0.55 0.11(-4.57, 8.33)

PGMS

9.00 (3.61) n = 9

9.92 (3.15) n = 13

0.72-0.08 (CI -3.42, 2.42)

9.57 (4.22) n = 14

9.11 (3.66) n = 18

0.48-0.13 (-4.06, 1.97)

HAP MAS

72.36 (14.01) n = 14

65.47 (13.71) n = 15

0.07-0.28(CI -16.15, 0.70)

67.07 (9.25) n = 14

67.11(14.10) n = 18

0.93 0.01 (-6.83, 7.41)

HAP AAS

60.21 (19.77) n = 14

54.13 (18.45) n = 15

0.28-0.14(CI -14.69, 4.46)

56.64 (14.59) n = 14

54.72 (18.83) n = 18

0.82 0.02 (-6.15, 7.65)

WHO QOL DOM 1**

12.45 (2.00) n = 14

12.25 (1.40) n = 16

0.36-0.16 (CI -1.71, 0.64)

13.39 (3.03) n = 14

12.42 (2.65) n = 18

0.05-0.28 (-3.19, 0.01)

WHO QOL DOM 2**

12.67 (1.01) n = 14

13.04 (1.54) n = 16

0.66 0.09 (CI -0.81, 1.25)

13.26 (1.69) n = 14

13.37 (2.03) n = 18

0.98-0.003 (-1.20, 1.18)

WHO QOL DOM 3**

13.76 (3.28) n = 14

13.50 (2.10) n = 16

0.63-0.10 (CI -2.68, 1.65)

13.90 (3.20) n = 14

13.44 (2.04) n = 18

0.59-0.10 (-2.55, 1.48)

WHO QOL DOM 4**

14.97 (2.13) n = 14

14.66 (1.82) n = 16

0.18-0.19 (CI -1.86, 0.38)

14.39 (2.42) n = 14

14.97 (2.24) n = 18

0.57-0.08 (-1.80, 1.02)

Self Efficacy

14.23 (4.88) n = 13

12.36 (4.45) n = 14

0.45-0.16 (CI -5.43, 2.48)

13.21 (5.05) n = 14

10.81 (3.83) n = 16

0.22-0.26 (-6.03, 1.46)

PASE

115.76 (47.59) n = 11

97.84 (69.57) n = 15

0.26-0.19 (CI -63.80, 18.15)

116.39 (49.13) n = 11

104.80 (69.07) n = 18

0.64-0.07 (-47.86, 30.19)